Articles related to GI CANCERS
Poor Outcomes Seen in Advanced Cancer Patients Treated with Inpatient ICI Therapy
According to a study presented at the 2022 ASCO Quality Care Symposium, 27% of 159 patients in the sample who received inpatient immune checkpoint inhibitor (ICI) treatment passed away while still in the hospital, with the median overall survival for the entire group being 47 days. Thoracic or head and neck cancers (27%) were the most prevalent, with gastrointestinal cancers (20%), hematologic malignancies (18%), genitourinary cancers (17%), and melanoma (11%) rounding out the rest.
Hematology/Oncology October 31st 2022
The Role of Circulating Tumor DNA in Evaluating Minimal Residual Disease in Luminal Gastrointestinal Malignancies
ctDNA provides an intriguing, noninvasive means of evaluating solid organ malignancies—from early diagnosis to personalized treatment decisions to prognosis and estimating risk of recurrence.
Oncology, Medical July 25th 2022